Fulgent Genetics Management
Management criteria checks 2/4
Fulgent Genetics' CEO is Ming Hsieh, appointed in May 2016, has a tenure of 8.67 years. total yearly compensation is $5.31M, comprised of 18.8% salary and 81.2% bonuses, including company stock and options. directly owns 28.54% of the company’s shares, worth $161.21M. The average tenure of the management team and the board of directors is 4.8 years and 3.9 years respectively.
Key information
Ming Hsieh
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 18.8% |
| CEO tenure | 8.7yrs |
| CEO ownership | 28.5% |
| Management average tenure | 4.8yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Fulgent Genetics: A Value Stock With Caveats (Rating Downgrade)
Dec 18Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Sep 25Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Sep 09Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio
Jul 17
Fulgent Genetics: Growth Is Returning
Jun 06Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package
May 10Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 07Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Feb 27Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Feb 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$165m |
| Jun 30 2024 | n/a | n/a | -US$163m |
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$5m | US$1m | -US$168m |
| Sep 30 2023 | n/a | n/a | -US$64m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$5m | US$948k | US$143m |
| Sep 30 2022 | n/a | n/a | US$272m |
| Jun 30 2022 | n/a | n/a | US$392m |
| Mar 31 2022 | n/a | n/a | US$461m |
| Dec 31 2021 | US$6m | US$664k | US$507m |
| Sep 30 2021 | n/a | n/a | US$569m |
| Jun 30 2021 | n/a | n/a | US$493m |
| Mar 31 2021 | n/a | n/a | US$417m |
| Dec 31 2020 | US$248k | US$240k | US$214m |
| Sep 30 2020 | n/a | n/a | US$48m |
| Jun 30 2020 | n/a | n/a | US$3m |
| Mar 31 2020 | n/a | n/a | -US$459k |
| Dec 31 2019 | US$240k | US$240k | -US$411k |
| Sep 30 2019 | n/a | n/a | -US$2m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | US$240k | US$240k | -US$6m |
Compensation vs Market: Ming's total compensation ($USD5.31M) is above average for companies of similar size in the US market ($USD2.14M).
Compensation vs Earnings: Ming's compensation has increased whilst the company is unprofitable.
CEO
Ming Hsieh (68 yo)
8.7yrs
Tenure
US$5,309,167
Compensation
Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 8.7yrs | US$5.31m | 28.54% $ 161.2m | |
| COO & President | 6.8yrs | US$1.79m | 1.47% $ 8.3m | |
| Chief Financial Officer | 9yrs | US$1.78m | 0.41% $ 2.3m | |
| Chief Scientific Officer & Laboratory Director | 8.3yrs | US$1.49m | 2.8% $ 15.8m | |
| General Counsel & Chief Privacy Officer | 2.7yrs | no data | no data | |
| VP of Operations & Compliance and GM of Houston Office | 4.3yrs | no data | no data | |
| Vice President of Business Development & Sales | 10yrs | no data | no data | |
| Vice President of Human Resources | 2.7yrs | no data | no data | |
| Chief Commercial Officer | 4.8yrs | no data | no data | |
| Chief Medical Officer | 3.7yrs | no data | no data | |
| President & Chief Scientific Officer of Fulgent Pharma | 2.2yrs | no data | no data |
4.8yrs
Average Tenure
58yo
Average Age
Experienced Management: FLGT's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 8.7yrs | US$5.31m | 28.54% $ 161.2m | |
| Independent Non-Employee Director | 2yrs | US$625.60k | 0.0039% $ 21.9k | |
| Independent Director | 5.4yrs | US$270.50k | 0.061% $ 344.6k | |
| Independent Non-Employee Director | 2.4yrs | US$268.50k | 0.0078% $ 44.0k |
3.9yrs
Average Tenure
67yo
Average Age
Experienced Board: FLGT's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 01:56 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fulgent Genetics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Karen Koski | BTIG |
| Andrew Cooper | CGS International |
| Erin Wilson Wright | Credit Suisse |